MCU

Across TCGA pan-cancer cohorts, MCU mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MCU data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MCU mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MCU expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

HNSC, COAD, and LUAD are the cancer types where MCU mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.812	0.481	.002	32	view →
COAD	DFS	Quartile	All	1.000	0.824	.027	30	view →
LUAD	DFS	Median	All	0.672	0.950	.009	9	view →
OV	DFS	Median	All	0.900	0.685	.029	8	view →
PDAC	DFS	Median	All	0.337	0.467	.023	6	view →
CCRCC	DFS	Quartile	II,III,IV	0.361	0.807	.012	5	view →
GBM	OS	Quartile	All	0.860	0.617	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MCU–HNSC (DFS)

Open the HNSC breakdown →